Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.65 |
| ▸ | F3 | P13726 | 1/20 | 0.65 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.65 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.65 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.65 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.65 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.65 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.65 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.49 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.46 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.46 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Niacinamide SCHEMBL5354739 | 0.92 | F7 (0.55) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL810864 | 0.84 | F7 (0.79) | F7F3SARM1SIRT2SIRT6 | |
| Citric Acid SCHEMBL27498577 | 0.82 | CYP3A4 (0.59) | ALDH1A1LMNAKMT2ATDP1CYP3A4 | |
| Niacinamide SCHEMBL675207 | 0.82 | F7 (0.96) | F7F3SARM1SIRT2SIRT6 | |
| Citric Acid SCHEMBL3644940 | 0.81 | ALDH1A1 (0.50) | ALDH1A1PLOD2PLOD3PLOD1LMNA | |
| Niacinamide SCHEMBL580103 | 0.81 | F7 (0.55) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL28768072 | 0.81 | F7 (0.79) | F7F3SARM1SIRT2SIRT6 | |
| Citric Acid SCHEMBL27663575 | 0.81 | CYP3A4 (0.57) | ALDH1A1LMNAKMT2ATDP1CYP3A4 | |
| Niacinamide SCHEMBL2926 | 0.80 | — | — | |
| Niacinamide SCHEMBL19978192 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116850073-A | Active substance eutectic solvent liposome face cream and preparation method thereof | 北京理工大学重庆创新中心 | 2023-10-10 | — | — | CN | claimed |
| CN-116236410-A | Ionic liquid cosmetic peptide stock solution and preparation method and application thereof | 武汉绿合医药科技有限公司 | 2023-06-09 | — | — | CN | claimed |
| US-20170360687-A1 | SUBSTRATE-BASED PRODUCT, ITS METHOD OF PREPARATION AND COSMETIC USES THEREOF | L'OREAL (FR) | 2017-12-21 | — | — | US | claimed |
| EP-3236922-A1 | SUBSTRATE-BASED PRODUCT, ITS METHOD OF PREPARATION AND COSMETIC USES THEREOF | L'OREAL (FR) | 2017-11-01 | — | — | EP | claimed |
| WO-2016102702-A1 | SUBSTRATE-BASED PRODUCT, ITS METHOD OF PREPARATION AND COSMETIC USES THEREOF | L'OREAL (FR) | 2016-06-30 | — | — | WO | claimed |
| CN-101031299-A | Thienopyridinone compounds and methods of treatment | EPIX DELAWARE INC (US) | 2007-09-05 | — | — | CN | claimed |
| US-20060147508-A1 | Concurrent Enhancement of Skin Penetration of Organic Base Active Agents and Organic Hydroxy Acid Active Agents as Their Ion-Pair Complexes | BIODERM RESEARCH (US) | 2006-07-06 | — | — | US | claimed |
| US-20040228884-A1 | Ion-pair delivery system for cosmetic and pharmaceutical compositions | GUPTA SHYAM K (US) | 2004-11-18 | — | — | US | claimed |
| US-20040156873-A1 | Topically Bioavailable Acne and Rosacea Treatment Compositions | GUPTA SHYAM K (US) | 2004-08-12 | — | — | US | claimed |
| US-20040092482-A1 | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions | GUPTA SHYAM K (US) | 2004-05-13 | — | — | US | claimed |
| CN-116850073-A | Active substance eutectic solvent liposome face cream and preparation method thereof | 北京理工大学重庆创新中心 | 2023-10-10 | — | — | CN | disclosed |
| CN-116236410-A | Ionic liquid cosmetic peptide stock solution and preparation method and application thereof | 武汉绿合医药科技有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20230025067-A1 | SOLID LOW FOAMING IN DISSOLUTION AND LOW PH ALL-PURPOSE CLEANER AND DISINFECTANT COMPOSITIONS | RECKITT BENCKISER LLC | 2023-01-26 | — | — | US | disclosed |
| CN-115554260-A | Effervescent composition comprising co-crystals of acid moieties | 布拉德福德大学 | 2023-01-03 | — | — | CN | disclosed |
| US-10420718-B2 | Effervescent compositions containing co-crystals of the acid part | UNIVERSITY OF BRADFORD (GB) | 2019-09-24 | — | — | US | disclosed |
| WO-2006023710-A2 | COSMETIC OR PHARMACEUTICAL COMPOSITION FOR SKIN CARE | INFINITY2 HEALTH SCIENCES, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060039887-A1 | Cosmetic or pharmaceutical composition for skin care | INFINITY2 HEALTH SCIENCES, INC. | 2006-02-23 | — | — | US | disclosed |
| US-20050037038-A1 | Cosmetic Dermabrasion Treatment System | GUPTA SHYAM K (US) | 2005-02-17 | — | — | US | disclosed |
| US-20040228884-A1 | Ion-pair delivery system for cosmetic and pharmaceutical compositions | GUPTA SHYAM K (US) | 2004-11-18 | — | — | US | disclosed |
| US-20040092482-A1 | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions | GUPTA SHYAM K (US) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092482-A1 | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions | CUTA, HIRA, HARS1 | F7 3378/4885F3 4156/4885SARM1 4221/4885 |
| US-10420718-B2 | Effervescent compositions containing co-crystals of the acid part | C9, SLC11A2, NPC1L1 | F7 2108/4885F3 4012/4885SARM1 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.